Soleno Therapeutics Future Growth
Future criteria checks 0/6
Soleno Therapeutics is forecast to grow earnings and revenue by 66.8% and 77% per annum respectively while EPS is expected to grow by 58.6% per annum.
Key information
66.8%
Earnings growth rate
58.6%
EPS growth rate
Biotechs earnings growth | 30.0% |
Revenue growth rate | 77.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | n/a |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | 37 | -18 | N/A | N/A | 2 |
12/31/2023 | N/A | -32 | N/A | N/A | 2 |
12/31/2022 | N/A | -28 | N/A | N/A | 2 |
6/30/2022 | N/A | -23 | -23 | -23 | N/A |
3/31/2022 | N/A | -28 | -27 | -27 | N/A |
12/31/2021 | N/A | -31 | -28 | -28 | N/A |
9/30/2021 | N/A | -31 | -28 | -28 | N/A |
6/30/2021 | N/A | -31 | -29 | -29 | N/A |
3/31/2021 | N/A | -28 | -27 | -27 | N/A |
12/31/2020 | N/A | -25 | -25 | -25 | N/A |
9/30/2020 | N/A | -36 | -23 | -23 | N/A |
6/30/2020 | N/A | -27 | -22 | -22 | N/A |
3/31/2020 | N/A | -30 | -19 | -19 | N/A |
12/31/2019 | N/A | -31 | -17 | -17 | N/A |
9/30/2019 | N/A | -16 | -16 | -16 | N/A |
6/30/2019 | N/A | -19 | -14 | -14 | N/A |
3/31/2019 | N/A | -16 | -13 | -13 | N/A |
12/31/2018 | N/A | -12 | -12 | -12 | N/A |
9/30/2018 | N/A | -16 | -11 | -11 | N/A |
6/30/2018 | N/A | -17 | -10 | -10 | N/A |
3/31/2018 | N/A | -13 | -10 | -10 | N/A |
12/31/2017 | N/A | -12 | -10 | -10 | N/A |
9/30/2017 | N/A | -13 | -10 | -10 | N/A |
6/30/2017 | 0 | -11 | -11 | -11 | N/A |
3/31/2017 | 0 | -9 | -12 | -12 | N/A |
12/31/2016 | N/A | -10 | -14 | -13 | N/A |
9/30/2016 | 0 | -8 | -14 | -14 | N/A |
6/30/2016 | 0 | -10 | -15 | -14 | N/A |
3/31/2016 | 1 | -7 | N/A | -12 | N/A |
12/31/2015 | N/A | -10 | N/A | -10 | N/A |
9/30/2015 | 0 | -20 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6XC1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6XC1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6XC1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6XC1 is forecast to have no revenue next year.
High Growth Revenue: 6XC1 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6XC1's Return on Equity is forecast to be high in 3 years time